Drugs / LY9999QS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03220126 | Jul 2017 → Feb 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY9999QS | “Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)” NCT03220126 ↗ |
| Route | Subcutaneous | “Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)” NCT03220126 ↗ |